1 March 2008 Monitoring singlet oxygen in situ with delayed chemiluminescence to deduce the effect of photodynamic therapy
Author Affiliations +
Abstract
Singlet oxygen (1O2) is an important factor mediating cell killing in photodynamic therapy (PDT). We previously reported that chemiluminescence (CL) can be used to detect 1O2 production in PDT and linked the signal to the PDT-induced cytotoxicity in vitro. We develop a new CL detection apparatus to achieve in vivo measurements. The system utilizes a time-delayed CL signal to overcome the interference from scattered excitation light, thus greatly improving the accuracy of the detection. The system is tested on healthy skin of BALB/ca mouse for its feasibility and reliability. The CL measurement is made during a synchronized gating period of the irradiation light. After each PDT treatment and in situ CL measurement, the skin response is scored over a period of 2 weeks. A remarkable relationship is observed between the score and the CL, regardless of the PDT treatment protocol. Although there are many issues yet to be addressed, our results clearly demonstrate the feasibility of CL measurement during PDT and its potential for in vivo PDT dosimetry. This requires further investigations.
© (2008) Society of Photo-Optical Instrumentation Engineers (SPIE)
Yanchun Wei, Xing Da, Shiming Luo, Wei Xu, Qun Chen, "Monitoring singlet oxygen in situ with delayed chemiluminescence to deduce the effect of photodynamic therapy," Journal of Biomedical Optics 13(2), 024023 (1 March 2008). https://doi.org/10.1117/1.2904961 . Submission:
JOURNAL ARTICLE
7 PAGES


SHARE
Back to Top